Decreased s.c. growth of CNDT 2.5 cells after systemic administration of DOPC liposome-conjugated siNRP-2. by Shaija Samuel (341436)

“…NRP-2-siRNA DOPC-treatment led to a significant decrease in tumor growth compared with cntr siRNA DOPC-treatment (264.4 mm³ vs. 751.3 mm³, respectively; *<i>p</i> = 0.01). …”

Inhibition of TNF and/or IL-1 pathways decreases release of CXCL8 and CCL5 but not CXCL10 and IFNs induced by influenza infection. by Jieru Wang (179734)

Inhibition of ERK 1/2 decreases GM-CSF- and IL-3-responsive Eo/B CFU, but not IL-5-responsive colonies. by Pia Reece (589971)

Resveratrol decreases activated-STAT1 levels in the nucleus of cytokine-stimulated HT-29 cells more efficiently than 5-ASA. by Diana Serra (455187)

Focal adhesion kinase phosphorylation levels within the optic nerve head decrease steadily after intraocular pressure elevation. by Shandiz Tehrani (3365900)

Cell adhesion was decreased by simvastatin and benznidazole during <i>Trypanosoma cruzi</i> infection. by Carolina Campos-Estrada (403914)

Intranasal administration of perindopril decreases amyloid plaques and CD11b staining in the cortex of 3-month old 5XFAD mice. by Nofar Torika (3169497)

Intranasal administration of telmisartan decreases amyloid plaques and CD11b staining in the cortex of 3-month-old 5XFAD mice. by Nofar Torika (3169497)

The Activation Effects of Low Level Isopropyl Alcohol Exposure on Arterial Blood Pressures Are Associated with Decreased 5-Hydroxyindole Acetic Acid in Urine by Zhiqiang Zhao (201543)

Sign-tracking (ST)–Goal-tracking (GT) score for day 5. by Silvia Fuentes (4759686)

Hepatic irradiation decreases the proportion of DX5^–TRAIL⁺ lrNK cells for up to two months. by Ryosuke Nakano (4557097)

“…NK cells were divided into DX5^–TRAIL⁺ lrNK cells and DX5⁺TRAIL⁻ cNK cells. …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: